Innovate UK Funding winners announced

The results of the 2015 Innovate UK competition in cell and gene therapy have recently been announced. The winning projects include:

- Next generation DNA constructs for the rapid and safe manufacture of AAV vectors for Regenerative Gene Therapy, led by Cobra Biologics Ltd
- Development of an Industrial Manufacturing Platform for AAV production to support Regenerative Gene Therapy products, also led by Cobra Biologics Ltd
- Enhanced Vector Bioprocessing Technologies for Cell and Gene Therapies, led by Synpromics Ltd
- Stem cell-derived exosomes for regenerative medicine, led by ReNeuron Ltd
- CAR Therapy for T Cell Malignancies, led by Autolus Ltd

For further information on the individual projects and on the additional partners involved in each, please click here.


CAR T cell meeting in New York, NY, US in March 2016

The Memorial Sloan Kettering Cancer Centre are holding a two day meeting on chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of cancer.

The meeting will be covering the translation of CAR T cell therapeutics from the bench to the bedside and will address a variety of topics, such as the selection of appropriate antigen targets, vector manufacture, QC, and regulatory hurdles.

Abstracts are also welcome from those wishing to present their work.

The meeting will take place from 10-11 March 2016 and the fee for registration starts at $75 for residents and fellows, and $200 for clinicians.

For further information on the programme, registration, and abstract submission, please click here.


3rd BIRAX conference in Oxford, UK in April 2016

The 3rd British Israel Research and Academic Exchange Partnership Regenerative Medicine Initiative (BIRAX) Conference is being held this spring in Oxford, UK. The two day meeting will cover the latest developments in the field and welcomes researchers worldwide.

The meeting will take place on 11-12 April 2016 and is being held at the University of Oxford.

For further information on the programme, registration, and abstract submission, please click here.


13th BSGCT Annual Meeting in London, UK in April 2016

The 13th Annual Meeting of the BSGCT is being held in April 2016 and will be focusing on the use of adeno-associated virus as a therapeutic vector.

The meeting will take place on 15 April 2016 at the UCL Institute of Child Health in London, UK.

For further information on the programme, registration, and abstract submission, please click here.


Pluripotent stem cell training course in London, UK in April 2016

UCL’s Department of Biochemical Engineering are offering a 3-day cell culture training course focusing on induced pluripotent stem cells (iPSC) and human embryonic stem cells (hESC). The course is designed for life science and engineering graduates new to stem cell culture, as well as for more experienced individuals new to working with iPSC or hES cell lines.

The course will take place from 27-29 April 2016 at UCL’s Department of Biochemical Engineering in London, UK.

For further information on the agenda and how to book for the course, please click here.


19th ASGCT Annual Meeting in Washington, DC, US in May 2016

ASGCT will be holding their 19th Annual Meeting in Washington, DC in May 2015. The agenda will feature clinical trial results, technology advancements, and networking opportunities, and keynote lectures will be given by Dr. David Liu, Dr. Alain Fischer and Dr. Theodore Friedmann.

The meeting will take place from 4-7 May 2016 at the Marriott Wardman Park Hotel in Washington, DC, US.

For further information on the programme, registration, and abstract submission, please click here.


11th World Stem Cells and Regenerative Medicine Congress in London, UK in May 2016

Terrapinn’s global gathering of the stem cell and regenerative medicine industrial communities will be taking place from 18-20 May 2015 at the Business Design Centre in London, UK.

The eleventh event in the series, the Congress has become the leading ‘go to’ event for cell therapy executives, and the agenda and networking opportunities ensure strong engagement with the delegates.

Terrapinn are kindly offering a 10% discount on registration for LRMN members. To take advantage of the discount, please use the booking code ‘YBEW’ when booking.

For further information on the programme and in order to register, please click here.


22nd ISCT Annual Meeting in Singapore in May 2016

ISCT will be holding their 22nd Annual Meeting in Singapore in May 2015. The agenda will be packed with industry, clinical and scientific talks, as well as the pre-conference Flow Cytometry workshops, Global Regulatory Perspectives event, and much more.

The meeting will take place from 25-28 May 2016 at the Suntec Convention and Exhibition Centre in Singapore.

For further information on the programme, registration, and abstract submission, please click here.


Cell Therapy Bioprocessing Congress in London, UK in June 2016

The Bioprocessing of Advanced Cellular Therapies Congress is being held this summer in London, UK from 2-3 June 2016.

The two days of talks will cover a variety of topics including scalable manufacturing, reimbursement models and regulatory requirements, and business development. Key speakers include representatives from University College London (UK), Genethon (France), GSK (UK), and Audentes Therapeutics (US).

Registration fees start at £495. For further information on the programme and registration, please click


ISCT guide on unproven cellular therapy for patients and the wider community

The International Society for Cellular Therapy (ISCT), the global society of clinicians, researchers, regulators, technologists, and industry partners dedicated to the translation of cellular therapy into safe and effective therapies to improve patients’ lives, in October 2015 published its reference guide on the use of unproven cellular therapies. The documentation has been authored by the ISCT Presidential Task Force, comprising 23 leading figures in the field of cell therapy. The publication, constructed over two and a half years, is the most recent and comprehensive initiative by ISCT to combat and raise awareness about unethical and unproven cellular therapies and medical tourism.

The guide includes information on the practice of unproven cell therapy, which involves in the region of 60,000 patients annually paying up to $40,000 per treatment. The guide is intended to be used by all who are involved in the cell therapy sector, and ISCT is at the forefront of this initiative to help all concerned make informed decisions about treatment options. The various sections of the guide define unproven cellular therapy, deal with industry issues including cell manufacturing, investigate globally diverse and contradictory regulations, demonstrate how unproven treatments negatively influence genuine cell-based products, propose action to improve communication among international monitoring organisations, and outline the next stage of the ISCT initiative to promote ‘proven cellular therapy’.

The document, entitled ‘ON UNPROVEN CELLULAR THERAPIES 2015. Talking About Unproven Cell-Based Interventions’ is available on the ISCT website
here, and will subsequently be published in the ISCT’s scientific journal Cytotherapy in January 2016.


Publication of RMEG report

The Regenerative Medicine Expert Group (RMEG) have published their report on how to support the growth of regenerative medicine in the UK.

The report provides recommendations for implementing a regenerative medicine delivery strategy, acknowledges and builds on existing initiatives, recommends further actions to support the adoption and spread of these innovative treatments in healthcare, and describes plans that will put the UK at the forefront of the application of regenerative medicine.

The report was published in March 2015 and is available to download


Atlas of Human Pluripotent Stem Cells in Culture published by Springer

An Atlas of Human Pluripotent Stem Cells in Culture, authored by Lyn Healy (UK Stem Cell Bank) and Ludmila Ruban (Dept. Biochemical Engineering, UCL), was published in 2015 and is now available from Springer Life Sciences.

The Atlas includes more than 280 illustrations and captions reflecting the best practices for culturing pluripotent stem cells, examining what ‘good quality’ cells look like and how they behave in different environments. Topics covered include human embryonic stem cells and induced pluripotent stem cells, as well as culture techniques for mouse and human fibroblasts, characteristic staining patterns, and abnormal culture types. The Atlas was published in late 2014 and is an invaluable resource for researchers, teachers, and laboratory personnel interested in or currently working in stem cell culture.

For further information, please click


Briefing notes for journalists on the topic of stem cell research from the Science Media Centre

In collaboration with journalists, scientists and press officers, the Science Media Centre (SMC) produces a number of publications designed to equip journalists with what they need to know. Having in-depth knowledge of issues across the sciences is a challenge for specialist journalists, let alone generalists, editors and broadcasters who may have to cover a great number of unrelated topics in a single day.

The SMC produces briefing notes on controversial topics in science which give a snapshot of the basics and a run-down of points of controversy from the scientific perspective. The LRMN was delighted to be part of the formation of a briefing note on the topic of stem cell research, and are highly supportive of encouraging effective communication of the field between scientists and journalists.

The briefing notes can be found
here or further information can be obtained by contacting the SMC via email.


Cell Therapy and Regenerative Medicine Glossary

The LRMN has worked together with the British Standards Institution (
BSI) and an expert advisory panel to revise the original Regenerative Medicine glossary, published both by BSI in 2008 and by Future Medicine in 2009. The most recent version, the Cell Therapy and Regenerative Medicine Glossary, PAS 84:2012, was published in May 2012 as a supplement to the journal Regenerative Medicine and is available here, as well as through the BSI website here.

The glossary contains definitions of all terms involved in the cell therapy and regenerative medicine sector, and has been developed to encourage the use of common terms and definitions within the field. It provides clear guidance on the meaning of terminology currently used in the UK by industry, regulators, government and academia. This aims to help the key stakeholders to communicate more effectively, as well as allowing the commercialisation of new technologies to take place more efficiently and safely.

Other relevant specifications include PAS 83:2012, Developing human cells for clinical applications in the European Union and the United States of America, which is available
here, and PAS 93:2011, Characterization of human cells for clinical applications, which is available here.